UroGen: Record JELMYTO Quarterly Sales and Recent Corporate Developments

 

• Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non‐muscle‐invasive bladder cancer (LG-IR-NMIBC).

• Reported record JELMYTO® net product revenues in Q2 2023 of $21.1 million, an increase of ~27% from the same period last year

• Significantly strengthened balance sheet via $120 million private placement of ordinary shares and pre-funded warrants

https://www.biospace.com/article/releases/urogen-pharma-reports-record-jelmyto-quarterly-sales-and-recent-corporate-developments/